[go: up one dir, main page]

NO20071028L - Kapsler som inneholder forbigaende transfekterte celler, fremgangsmater for fremstilling derav og anvendelser derav. - Google Patents

Kapsler som inneholder forbigaende transfekterte celler, fremgangsmater for fremstilling derav og anvendelser derav.

Info

Publication number
NO20071028L
NO20071028L NO20071028A NO20071028A NO20071028L NO 20071028 L NO20071028 L NO 20071028L NO 20071028 A NO20071028 A NO 20071028A NO 20071028 A NO20071028 A NO 20071028A NO 20071028 L NO20071028 L NO 20071028L
Authority
NO
Norway
Prior art keywords
transiently transfected
applications
processes
preparation
transfected cells
Prior art date
Application number
NO20071028A
Other languages
English (en)
Norwegian (no)
Inventor
Patricia De Lys
Thierry Battle
Ursula Boschert
Holger Heine
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20071028L publication Critical patent/NO20071028L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20071028A 2004-08-04 2007-02-23 Kapsler som inneholder forbigaende transfekterte celler, fremgangsmater for fremstilling derav og anvendelser derav. NO20071028L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405494 2004-08-04
PCT/IB2005/002294 WO2006016238A2 (fr) 2004-08-04 2005-08-02 Capsules contenant des cellules transitoirement transfectées, procédé servant à préparer celles-ci et utilisations de celles-ci

Publications (1)

Publication Number Publication Date
NO20071028L true NO20071028L (no) 2007-02-23

Family

ID=34932229

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071028A NO20071028L (no) 2004-08-04 2007-02-23 Kapsler som inneholder forbigaende transfekterte celler, fremgangsmater for fremstilling derav og anvendelser derav.

Country Status (8)

Country Link
US (1) US20070258901A1 (fr)
EP (1) EP1773990A2 (fr)
JP (1) JP2008509127A (fr)
AU (1) AU2005270968A1 (fr)
CA (1) CA2572326A1 (fr)
IL (1) IL181006A0 (fr)
NO (1) NO20071028L (fr)
WO (1) WO2006016238A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734823B2 (en) 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8682619B2 (en) 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8551749B2 (en) * 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5453270A (en) * 1992-03-30 1995-09-26 Hypermetabolic Therapies, Inc. Pharmaceutical composition and method for hypermetabolic weight loss
EP0662133B1 (fr) * 1992-09-18 2009-11-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Proteines recombinees d'une souche pakistanaise du virus de l'hepatite e et leur utilisation dans des procedes diagnostiques et des vaccins
US5902576A (en) * 1992-10-22 1999-05-11 Yeda Research And Development Co. Ltd. At Weizmann Institute Of Science Antitumor pharmaceutical composition comprising IL-6 transfected cells
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
JP3810791B2 (ja) * 1993-09-10 2006-08-16 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 緑色蛍光タンパク質の使用
US6254873B1 (en) * 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
US6027881A (en) * 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
CA2286349A1 (fr) * 1997-04-08 1998-10-15 Thomas John Goodwin Elaboration de proteines fonctionnelles : equilibre entre contrainte tangentielle et gravite
EP1062032B1 (fr) * 1998-03-07 2004-03-31 Inotech Ag Procede et dispositif pour encapsider des cellules microbiennes, vegetales et animales ou bien des substances biologiques et chimiques
US6221613B1 (en) * 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
US20040005302A1 (en) * 2002-04-30 2004-01-08 Gonzalo Hortelano Encapsulated cells to elicit immune responses

Also Published As

Publication number Publication date
CA2572326A1 (fr) 2006-02-16
US20070258901A1 (en) 2007-11-08
JP2008509127A (ja) 2008-03-27
EP1773990A2 (fr) 2007-04-18
IL181006A0 (en) 2007-07-04
WO2006016238A3 (fr) 2006-08-17
AU2005270968A1 (en) 2006-02-16
WO2006016238A2 (fr) 2006-02-16

Similar Documents

Publication Publication Date Title
NO20071028L (no) Kapsler som inneholder forbigaende transfekterte celler, fremgangsmater for fremstilling derav og anvendelser derav.
KR20170072236A (ko) 실라짓의 사용에 의한 근육 형성과 복구의 증진, 및 콜라겐 및 관련 단백질과 관련된 장애의 치료
Baek et al. Mollugin from Rubea cordifolia suppresses receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorbing activity in vitro and prevents lipopolysaccharide-induced bone loss in vivo
JP2019520837A (ja) Β細胞ミメティック細胞
Lema-Pérez Main Organs Involved in Glucose
Tian et al. Hollow microfiber assembly‐based endocrine pancreas‐on‐a‐chip for sugar substitute evaluation
Kumar et al. Formulation and characterization of bilayer floating tablets of ranitidine
Rai et al. [Retracted] Evaluation by an Aeronautic Dentist on the Adverse Effects of a Six‐Week Period of Microgravity on the Oral Cavity
BRPI0808801A2 (pt) Formulação farmacêutica.
CA2653929A1 (fr) Procede de criblage pour un prokinetique
Amritha et al. A review on pulsatile drug delivery system: drug scheduling based on biological rhythm
Gu et al. Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers
JP7698092B2 (ja) 新規な経口組成物
CN104490802B (zh) 红景天苷肠溶片及其制备方法
Coppola et al. Plant-To-plant communication triggered by systemin primes anti-herbivore resistance in tomato (173 views)
CN108670958A (zh) 一种伏格列波糖泡腾片的制备方法
CN103720674B (zh) 法莫替丁漂浮-粘附型微片胶囊及其制备方法
Peng et al. Masterful macrophages: understanding and targeting activation dysfunction in diabetic wounds
Sarkhejiya et al. Newer insights into pulsatile drug delivery systems
CA2532714A1 (fr) Comprime a liberation prolongee pour l'administration par voie orale
Puginier Biosensors for open and closed-loop glycemia control
JAYAKUMARI et al. Pulsatile drug delivery system-a novel approach for time and versatile rate-controlled drug delivery.
FIROZ et al. Oral Pulsatile Drug Delivery System-A Review.
JASSEM et al. A Novel Pulsatile Drug Delivery Approach–A Laconic Review.
Dev Neuromodulation of the Gut-Brain Axis and Its Influence on Sleep in Space

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application